👏 great summary of UC.

Transformative results of EV-302 nicely summarized in this NEJM Quick Take video! But how to move forward for mUC now?🤔 Identifying biomarkers of resistance to EV+PEM is key to further improve outcomes for mUC 🔎 The most intuitive biomarker for predicting response/

🎉 Just received an email from ASCO Communication featuring the article I wrote for CancerDotNet Grateful for the opportunity to contribute to such an esteemed platform Check out the article for insights on cancer.net/blog/2024-02/b…

Amazing results. Congratulations to Tom and team. Great opportunity to reduce the number of patients being over treated #EAU

This is great news to patients and care-givers. Strong signal, which may not have been anticipated after the AMBASSADOR data. Would have loved to see the PD-L1 neg. population.

Such a great idea and phantastic experience 🙏

Another piece of data, which showed benefit of IO in favorable risk patients: 👉Late separation of OS curves favoring AXI-AVE

👏 great presentation by Wolfgang Fendler on predictive value of PET 👉 PSMA PET metrics from 1,600+ pts. predict oncological outcomes in prostate patients 👉 new measure to assess risk in PC pts.

Bull's-eye. Great throw and even better hit. Congrats 👍

Es gibt eine neue Folge bei #onkowissenAUDIO zu #KopfHalsTumoren. PD Dr. Konrad Klinghammer und Dr. Michael Pogorzelski diskutieren mit Prof. Diana Lüftner (Prof. Dr. med. Diana Lüftner) die neuesten Entwicklungen & Standards in der Behandlung. Nicht verpassen: onkowissen.audio/podcasts/kopf-…

The #HEAT is on. Update on #SCCHN treatment and discussion of our new #platform study for real-world data in Germany. Arbeitsgemeinschaft Internistische Onkologie - AIO

brief, crisp and straight from Chicago.

great group and detailed discussion. I hope you find it as enjoyable as I did.

Clinical trial question: If your patient is eligible for RCT, and field has equipoise, but you personally believe one arm is better than the other, you should: 1. Enroll on RCT. You don't know the answer. 2. Do what you think is best for your patient, even if evidence not there

Same for me. Inform the patient about the data, risks and benefits and let them decide

Uromigos welcome to our dear friends from Germany!

Thank you Petros. We navigated through football, American presidents and cancer studies✌️

Absolutely. Phantastic people and great experience.

Real-world #cabozantinib after ICI: 👉 similar efficacy (shorter OS) compared to METEOR 👉 62% had lower starting doses (<60mg) 👉 similar outcome in low vs. 60 mg starting dose 👉 less toxicity with lower dose 👉 let's re-think cabozantinib dosing Axel S. Merseburger Toni Choueiri, MD

#sunniforecast investigated whether IPI-NIVO is superior to SOC (mainly TKI single agent) in ncc-RCC subtypes. All pts. had central pathology. IPI-NIVO had superior OS and supports its role in these rare subtypes. The benefit in chRCC was unexpected. PD-L1+ had highest benefits